Both subjective appetite ratings and hedonic hunger are easy to measure in clinical settings and could be helpful tools for personalizing obesity treatment, by adding behavior programs and/or incretin-mimetic drugs, namely GLP-1 receptor agonists, or drugs that target the brain’s reward pathways in those patients at risk for suboptimal WL post-RYGB. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.